MONTREAL, Aug. 25, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company, is making headlines with the announcement of a significant presentation at the upcoming European Society of Cardiology (ESC) Congress 2025, held from August 29 to September 1 in Madrid, Spain. The company is set to unveil groundbreaking preclinical results related to its lead compound, THRV-1268, which has the potential to revolutionize treatment options for serious cardiac conditions such as Long QT Syndrome (LQTS), heart failure, and atrial fibrillation.

2. Highlighting Dr. Saumya Das's Presentation

Dr. Saumya Das, Co-Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, will present compelling findings from Thryv’s research. The presentation is scheduled for Saturday, August 30, from 1:15 – 2:00 p.m. CET at the Research Gateway.

Presentation Details

Title: *THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure*

Location: Station 4 (Research Gateway)

Format: Moderated e-Poster

Session Link: SGLT2 Inhibitors in Heart Failure Prevention and Treatment – ESC365

Dr. Das’s presentation will focus on results derived from a Transaortic Constriction (TAC) preclinical model that evaluates the efficacy of THRV-1268 in comparison to Jardiance® (empagliflozin), a current standard treatment for heart failure. The findings highlight the potential of SGK1 inhibition as a strategic approach to combat inflammation and fibrosis-driven cardiac remodeling, critical factors in the progression of heart failure.

3. Collaborative Research on Long QT Syndrome

In addition to Thryv’s own presentation, the ESC 2025 will also feature research conducted by the European Joint Programme on Rare Diseases (EJPRD). This collaborative work provides robust evidence supporting SGK1 inhibition as an effective strategy in managing Long QT Syndrome (LQTS) by demonstrating its effects on late sodium current and action potential duration in various preclinical models.

Additional Presentation

Another significant presentation will be delivered by Simona Casini from the Amsterdam University Medical Centre (AUMC) on Sunday, August 31, from 1:25 – 2:15 p.m. CET.

Title: *SGK1 inhibition shortens action potential duration and exerts anti-arrhythmic effects in LQT3 mice and LQT2 rabbits by reducing enhanced late sodium current*

Location: Science Box 4 (Research Gateway)

Format: Abstract Session

Session Link: Molecular and Cellular Drivers of Arrhythmia – ESC365

4. The Future of SGK1 Inhibition

Thryv Therapeutics is at the forefront of advancing a series of selective SGK1 inhibitors targeting the underlying mechanisms contributing to serious cardiac conditions. By addressing inflammation, structural remodeling, electrical remodeling, and fibrosis, these inhibitors hold promise for transforming treatment paradigms in cardiometabolic diseases.

5. About Thryv Therapeutics

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada, dedicated to pioneering a precision medicine approach aimed at treating Long QT Syndrome, heart failure, and atrial fibrillation. Through its innovative work on SGK1 inhibitors, Thryv is setting the stage for significant advancements in cardiac therapeutics.

For more information about Thryv's research and products, interested individuals can visit their official website.

As the ESC Congress approaches, the scientific community eagerly anticipates the unveiling of Thryv's promising research, which could pave the way for new therapeutic strategies in the management of cardiac diseases.

Original press release